Eli Lilly said on Thursday that the U.S. Food and Drug Administration has approved its therapy for the treatment of metastatic breast cancer in patients whose disease progressed after at least one lin... ...

Accessibility StatementSkip Navigation An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo monotherapy reduced the risk of progression or death by 38% versus endocrine therapy among patients with ESR1-mutated MBC INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:Â LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Inl ...

PresentationOperator Hello, and welcome to the Annual Meeting of Shareholders of Medexus Pharmaceuticals Inc. Please note that today's meeting is being recorded. If you participate in today's meeting and disclose personal information, you will be deemed to consent to the recording, transfer and use of the same. If you disclose personal information of another person in today's meeting, you will be deemed to represent and warrant to Medexus and to the host of this webcast and all other relevant parties that y ...

PresentationOperator I would like to welcome everyone to the call today. We are joined by the CEO, Nils Ollquist. Before we begin, I'll go over the formality of reading the forward-looking statement, and then I'll turn it over to Nils. Except for historical information contained in this presentation, certain of the matters discussed in the communication contribute forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Words such as may, might, will, should, could, an ...

PresentationCourtney BreenSanford C. Bernstein & Co., LLC., Research Division Fantastic. Hi, everyone. Thank you so much for being with us here today, and I am thrilled to have with me Lucas Montarce, the CFO of Lilly; and Mike Czapar, I'm going to say the last name incorrectly, undoubtedly, the Head of IR for Lilly as well. For those of you who do not know me, my name is Courtney Breen. I am the U.S. large-cap pharma analyst here at Bernstein. And I feel very privileged to share the stage with these 2 here ...

My previous bullish call on Eli Lilly (NYSE: LLY ) hasn’t quite worked out as I’d hoped. Since March, the stock has dropped 10%, which is frustrating. Nevertheless, I believe the short-term price moves aren’t a true reflectionComing from an IT background, I have dived into the U.S. stock market seven years ago by managing portfolio of my family. Starting managing real money has been challenging for the first time, but long hours of mastering fundamental analysis of public companies paid off and now I feel v ...

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P 1500 Health Care Index declined 6.9% in the second quarter, underperforming the S&P 500’s 10.9% return. Health care providers & services, life science ...

一个曾被遗忘近20年的来靶点，正在成为搅动千亿减重市场的新爆点。 9月16日，诺和诺德在欧洲糖尿病研究协会大会（EASD）上公布了Amylin类似物cagrilintide（卡格列 肽）的3期REDEFINE 1研究最新数据。结果显示：治疗68周后，cagrilintide单药治疗实现了11.8%的平 均体重减轻。 更引人瞩目的是，其与司美格鲁肽组成的复方制剂CagriSema，平均减重效果达20.4%，显著优于单药 治疗。与此同时，CagriSema组的胃肠道副作用明显低于司美格鲁肽，做到了控糖与安全性的兼顾。 诺和诺德的布局远不止于此。9月22日，诺和诺德在Clinicaltrials.gov网站上注册了NNC0662-0419用于减 重的2期临床试验，该药物是GLP-1/GIP/Amylin三靶点激动剂（NN9662）。 同日，辉瑞宣布以49亿美元现金以及24亿美元里程碑付款的方式收购Metsera公司，此举动意在强化自 身的减重管线。消息一出，Metsera股价大幅飙升，一度暴涨超63%。 在此之前，罗氏、阿斯利康、礼来、艾伯维等多家国际药企已纷纷通过BD合作或重金收购等方式，加 速押注Amylin。 ...

Eli Lilly (NYSE:LLY) FY Conference September 25, 2025 08:00 AM ET Company ParticipantsLucas Montarce - EVP & CFOMichael Czapar - SVP - IRConference Call ParticipantsCourtney Breen - Senior Research Analyst - US BiopharmaCourtney BreenFantastic. Hi, everyone. Thank you so much for being with us here today. I am thrilled to have with me Lucas Montarce, CFO of Lilly, and Mike Czapar, and I'm going to say your last name incorrectly, undoubtedly the Head of IR for Lilly as well. For those of you who do not know ...

已终止的试验原计划对180名患有2型糖尿病且肥胖或超重的患者进行约13个月的随访。其主要观测指标 是体重减轻程度，但关键的次要衡量标准是体脂减少量。 根据美国临床试验登记处周三晚些时候更新的信息，礼来公司于6月10日终止了该试验，此时距试验启 动尚不足一个月。该网站显示，一项针对非糖尿病肥胖患者的类似研究仍保持活跃。 在礼来8月发布的第二季度财报演示中，该公司曾预计这项糖尿病试验将于2026年10月前得出结果。 在6月下旬公布的一项被视为bimagrumab概念验证的研究中，礼来表示该药物能帮助患者在服用竞争对 手诺和诺德的减肥药Wegovy减重时维持肌肉量。 该化合物旨在阻断一个通常调节肌肉生长的受体，其原研开发商诺华集团约八年前曾在一项小型研究中 对糖尿病患者进行过测试。在诺华早期研究中，37名接受bimagrumab治疗的患者里有一人出现胰腺炎 并住院。一些研究表明糖尿病患者可能面临更高的胰腺炎风险。 智通财经APP获悉，制药巨头礼来(LLY.US)已停止一项旨在防止肥胖患者肌肉过度流失的实验性药物研 究，理由是出于战略性商业考量。 这款实验性注射液是礼来应对快速减重患者常见肌肉流失策略的核心产品。包括 ...